Tumor Cells Recruit Macrophage Bodyguards to Outlast Chemotherapy

Tumor Cells Recruit Macrophage “Bodyguards” to Outlast Chemotherapy

What if cancer cells could recruit the body's own immune cells to help them survive treatment? Emerging research suggests that some tumors can interact with macrophages—immune cells that normally help defend and repair tissues—and reshape their behavior to support tumor survival.

In this article, we explore how tumor cells communicate with macrophages, how these immune cells can become part of the tumor microenvironment, and why this interaction may contribute to resistance to chemotherapy. Understanding these “macrophage bodyguards” could help researchers develop new strategies that target not only cancer cells themselves, but also the supportive environment that helps them persist.

Discover the science behind tumor–macrophage interactions, chemotherapy resistance, and the ongoing search for more effective cancer treatments.

When Cancer Turns the Immune System Into an Unexpected Ally

Imagine a city under attack. The police arrive, the streets are cleared, and the threat appears to be under control. But hidden among the crowd are people quietly helping the attackers rebuild, find shelter, and regroup.

Something surprisingly similar can happen inside a tumor.

Cancer cells do not live alone. They grow within a busy neighborhood of blood vessels, connective tissue, signaling molecules, and immune cells called the tumor microenvironment. Among the most important residents are macrophages—immune cells whose normal jobs include cleaning up damaged tissue, responding to injury, and helping coordinate repair.

In some tumors, cancer cells can influence these macrophages and turn them into tumor-associated macrophages (TAMs). Instead of strongly attacking the tumor, certain TAM populations can create conditions that help cancer cells survive, grow, spread, and sometimes become harder to eliminate with treatment.

That is where the idea of macrophages as cancer’s “bodyguards” comes from. It is a useful analogy—not a literal description—but it captures an important scientific concept: the cells surrounding a tumor can influence how well cancer treatment works.

Tumor-associated macrophages

What Exactly Are Macrophages?

Macrophages are part of the immune system and are found throughout the body. Think of them as adaptable maintenance and defense cells. They can engulf cellular debris, respond to signals from injured tissue, and communicate with other immune cells.

The important word is adaptable. Macrophages can change their behavior depending on the signals around them. Tumors can exploit this flexibility by producing chemical signals that attract macrophages and influence their functions. TAMs can therefore be highly diverse rather than one uniform type of immune cell.

This flexibility is one reason researchers are interested in macrophages as possible targets for cancer therapy.

How Does a Tumor Recruit Its “Bodyguards”?

Growing tumors release signaling molecules that can attract monocytes—the circulating cells that can develop into macrophages—toward the tumor. Signals such as CCL2, CCL5, and M-CSF have been implicated in macrophage recruitment and development within tumors.

Once inside the tumor environment, these cells encounter a very different set of instructions from those they would receive in healthy tissue. Oxygen levels, growth factors, cytokines, cancer-cell signals, and tissue damage can all influence macrophage behavior.

The result is a complicated relationship: the tumor can effectively create an environment in which some macrophages perform functions that benefit the cancer rather than the patient.

Who are the tumor-associated macrophages?

Macrophages are normally first responders: they engulf pathogens, clear debris, and coordinate immune attacks. But tumors are skilled at corrupting this system. Solid tumors recruit macrophages from two main sources — monocytes drawn in from the bloodstream by tumor-secreted chemokines, and resident macrophages already living in the tissue <cite index="6-1">which are important components of the tumor microenvironment (TME), with monocytes recruited to the tumor site by chemokines and other macrophages derived from tissue-resident cells inherent to the tumor site</cite>.

Once inside the tumor, macrophages don't stay neutral. <cite index="9-1,9-1">Within the tumor mass, tumor-associated macrophages have been shown to be fundamental for cancer progression</cite>, and in many solid tumors they are, by cell count, the single largest immune population present. Far from patrolling for threats, many of these macrophages are reprogrammed by the tumor into an "M2-like" state that suppresses immune attack and actively nurses cancer cells through treatment.

The evidence that TAMs matter for treatment outcomes is not just correlational. <cite index="2-1">Studies that experimentally deplete macrophages from tumors have repeatedly found that tumors become more sensitive to chemotherapy as a result</cite> — a strong signal that the macrophages themselves are actively blunting drug effects, rather than simply being bystanders in a resistant tumor.

How the Cancer bodyguards do their job

Researchers have mapped out several distinct tactics TAMs use to shield cancer cells from chemotherapy.

1. Chemical neutralization of the drug itself. 

In pancreatic cancer, TAMs secrete deoxycytidine, a molecule that directly interferes with gemcitabine's ability to trigger cell death, effectively defusing the drug before it can do damage <cite index="2-1">.</cite> Similar macrophage-driven resistance has been documented against other frontline chemotherapy agents, <cite index="2-1">including paclitaxel, doxorubicin, and etoposide</cite>.

2. Pumping the drug back out. 

Cancer cells often survive chemotherapy by expelling it through membrane transporter proteins. TAMs can help drive this process directly. In colorectal cancer, researchers recently traced a full signaling relay — <cite index="3-1">a CXCL17/CXCL22–CCR4–ATF6–GRP78 signaling axis running between macrophages and tumor cells</cite> — that promotes the drug-pump protein MRP1 to move to the tumor cell's surface, letting the cell flush out 5-fluorouracil, a chemotherapy staple, before it can act.

Cancer cells often survive chemotherapy by expelling it through membrane transporter proteins

3. Feeding tumor cells a metabolic escape route. 

A 2025 study found that chemotherapy itself can trigger this bodyguard response: treatment induces macrophages to ramp up CXCL7 production, which pushes a metabolic pathway (STAT1/PHGDH-driven serine synthesis) that both helps tumor cells survive treatment and reinforces the macrophages' own protective, tumor-favoring identity — a self-reinforcing feedback loop between drug exposure, tumor metabolism, and macrophage behavior.

STAT1/PHGDH-driven serine synthesis

4. Shielding cells from DNA damage. 

Beyond drug efflux and neutralization, TAMs support cancer cells' internal defenses too — boosting their <cite index="2-1">capacity for DNA repair, suppressing apoptosis (programmed cell death), and inducing protective autophagy</cite>, all of which help tumor cells absorb chemotherapy-induced damage without dying.

5. Guarding specific drug classes. 

Even classic, decades-old chemotherapy drugs aren't exempt. Macrophage-derived signals involving nitric oxide and sphingolipid metabolism have been linked to resistance against cisplatin, one of the most widely used chemotherapy agents in solid tumors.

Why this matters clinically-Why its important to Understand Tumor deference to Chemo

This isn't a peripheral finding — it may help explain a pattern oncologists have long observed: initial chemotherapy response followed by relapse, even when the tumor cells themselves haven't obviously mutated into resistant clones. <cite index="4-1">Higher infiltration of M2-like macrophages is consistently linked to worse clinical outcomes</cite> across multiple cancer types, and mechanisms of chemoresistance can arise not just from the tumor cells themselves but from these supportive stromal partners.

Importantly, the tumor doesn't just recruit passive helpers — it actively converts them. <cite index="6-1">Preclinical studies show that TAMs, following exposure to antitumor agents, can be reprogrammed toward an immunosuppressive, pro-blood-vessel-growth phenotype through various mechanisms</cite>, meaning chemotherapy itself can inadvertently train the tumor's bodyguard force to be more effective.

Fighting back: Disarming the Cancer bodyguards

If macrophages are propping up tumor resistance, an obvious strategy is to target them alongside — or instead of — the cancer cells directly. Several approaches are now in various stages of development:

• Blocking macrophage recruitment/survival. The CSF1/CSF1R signaling axis is the most heavily studied target, since it's essential for macrophage survival and recruitment into tumors. <cite index="14-1">Various approaches targeting either the CSF1 ligand or the CSF1R receptor are currently in clinical development</cite>, and one such drug, pexidartinib, has already been approved for a macrophage-driven (though non-malignant) tumor of the joint. Encouragingly, <cite index="14-1">emerging data on the tolerability of CSF1/CSF1R-targeting agents suggest a favorable safety profile</cite>, making them attractive to pair with existing treatments.

• "Reprogramming" rather than depleting. Instead of eliminating TAMs outright, newer strategies try to flip them back toward an anti-tumor state. A 2025 study of the covalent CSF1R inhibitor FF-10101 found it <cite index="10-1">reduced immunosuppressive TAMs while increasing antitumor TAMs in the tumor microenvironment, in turn boosting tumor-antigen-specific CD8+ T cells and significantly slowing tumor growth</cite> in animal models — evidence that shifting macrophage identity, not just removing macrophages, can restore treatment sensitivity.

• Combination approaches. In triple-negative breast cancer — a subtype notorious for chemo and immunotherapy resistance — a heavily macrophage-infiltrated, T-cell-poor microenvironment has been directly linked to standard-of-care treatment failure, spurring active research into anti-CSF1R therapy combined with chemo-immunotherapy regimens to convert these "cold" tumors into ones the immune system can actually fight.

The Bigger Lesson: Cancer Is an Ecosystem

For decades, cancer research understandably focused heavily on the cancer cell itself: its DNA, mutations, uncontrolled growth, and ability to spread.

Today, scientists increasingly view cancer as an ecosystem.

Cancer cells communicate with immune cells. Immune cells communicate with blood vessels. Fibroblasts alter the surrounding tissue. Signaling molecules pass messages between different cell populations. Together, these interactions can influence tumor growth and treatment response.

This broader view may help explain why two tumors that look similar under a microscope can sometimes respond differently to the same treatment.

What Does This Mean for the Future of Cancer Treatment?

The macrophage story points toward a future in which cancer treatment may target several parts of the tumor ecosystem at once.

Rather than focusing exclusively on destroying cancer cells, scientists are exploring combinations that could attack the tumor while also changing the environment that protects it.

The concept is simple to understand, even though the biology is remarkably complex: if the tumor has recruited cellular allies, perhaps treatment can be designed to remove the support those allies provide.

Researchers are still uncovering exactly which macrophage populations matter most in each cancer and which strategies can safely manipulate them. Much of the evidence comes from laboratory studies, animal models, and early clinical research, so promising findings do not automatically mean a new treatment is ready for routine patient care.

Final Thought

Cancer is not simply a group of cells growing out of control. It is a constantly changing community in which cancer cells communicate with—and sometimes manipulate—their surroundings.

Macrophages are a fascinating example. Cells designed to protect and repair the body can, under certain tumor conditions, become part of the support system that helps cancer survive.

Understanding these cellular relationships may eventually allow scientists to make cancer treatments more precise: not only attacking the tumor, but also disrupting the environment that helps it endure.

References

1. Larionova, I. et al. "Tumor-associated macrophages and cancer-associated fibroblasts confer chemoresistance to tumor cells." Frontiers in Cell and Developmental Biology, 2018. DOI: 10.3389/fcell.2018.00131
2. "Spatial organization of mediated-macrophage chemoprotective niches in solid tumors: A mathematical analysis." bioRxiv, 2024. DOI: 10.1101/2024.11.21.624654
3. Zhang, L. et al. "Tumor-associated macrophages confer colorectal cancer 5-fluorouracil resistance by promoting MRP1 membrane translocation via an intercellular CXCL17/CXCL22–CCR4–ATF6–GRP78 axis." Cell Death and Disease, 14, 2023. DOI: 10.1038/s41419-023-06108-0
4. "Progress in the Research on the Role of Tumor-associated Macrophages in Drug-resistance and Treatment of Tumors." Xiehe Yixue Zazhi, 2022.
5. Liu, S. et al. "Chemotherapy-induced macrophage CXCL7 expression drives tumor chemoresistance via the STAT1/PHGDH-serine metabolism axis and SAM paracrine feedback to M2 polarization." Cell Death and Disease, 16, 2025. DOI: 10.1038/s41419-025-07712-y
6. "Targeting tumor-associated macrophages to reverse antitumor drug resistance." PMC, 2024. PMC11210230
7. "Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance." npj Precision Oncology, 2024.
8. "Nitric oxide, acid sphingomyelinase, and syntaxin 4 in TAM-mediated cisplatin resistance." Frontiers in Immunology, 2018. DOI link via Frontiers
9. Kanno, K. et al. "Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages." JCI Insight, January 2025. PMC11721313
10. "Anti-CSF-1R therapy with combined immuno-chemotherapy coordinates an adaptive immune response to eliminate macrophage-enriched triple negative breast cancers." bioRxiv, May 2025. PMC12191229
11. Cannarile, M.A. et al. "Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy." Journal for ImmunoTherapy of Cancer, 2017. DOI: 10.1186/s40425-017-0257-y

This post is intended for general audiences interested in cancer biology and is not medical advice. Consult an oncologist for information relevant to individual diagnosis or treatment.

Brian Opiyo ( KRCHN, BScN)

Radioactive Fallout and Cancer: Lessons from Hiroshima, Nagasaki, Chernobyl, and Modern Conflict Risks

 

Radioactive Elements, Cancer Risk, and Historical Nuclear Incidents: Quantitative Risk Assessment and Implications for Modern Conflicts

Abstract

Radioactive elements are potent carcinogens due to their emission of ionizing radiation, which damages DNA and can induce malignancies. Historical nuclear events such as the atomic bombings of Hiroshima and Nagasaki, along with the Chernobyl nuclear disaster, provide critical epidemiological data for assessing radiation-induced cancer risk. This article synthesizes mechanisms of radiation-induced carcinogenesis, quantitative dose–response modeling, and historical cohort analyses, and extrapolates findings to contemporary conflict scenarios involving depleted uranium munitions or potential nuclear facility hazards, including the Middle East context. An annotated reference list provides robust scientific support.

1. Introduction

Radioactive elements, characterized by unstable atomic nuclei, emit ionizing radiation in the form of alpha, beta, or gamma rays. Unlike non-ionizing radiation, ionizing radiation carries sufficient energy to remove electrons from atoms, creating ions that can damage biological molecules. The health risks associated with radioactive exposure are most acutely observed in DNA damage, which, if not properly repaired, can initiate carcinogenesis.

In modern conflict contexts, the risk of radiation exposure arises both from military applications, such as depleted uranium (DU) munitions, and from potential attacks on nuclear facilities. Understanding cancer risk requires integrating data from historical incidents where populations were exposed to high levels of radiation, notably Hiroshima and Nagasaki (1945) and Chernobyl (1986). These events provide empirical data for dose-response modeling, which is crucial for estimating risk in contemporary low-dose exposures.

This article addresses:

1. Mechanisms of radiation-induced cancer
2. Quantitative dose-response modeling
3. Historical evidence from Hiroshima, Nagasaki, and Chernobyl
4. Risk assessment in modern conflict scenarios
5. Public health and policy implications

---

2. Mechanisms of Radiation-Induced Cancer

2.1 Ionizing Radiation and DNA Damage

Ionizing radiation produces free radicals that directly and indirectly damage cellular DNA. Damage manifests as:

• Single-strand breaks (SSBs): Generally repairable, minor effect if correctly repaired
• Double-strand breaks (DSBs): High risk of misrepair, can lead to mutations or chromosomal rearrangements
• Base modifications and crosslinking: Can disrupt gene transcription and replication

Persistent DNA damage can transform normal cells into cancerous cells, particularly when mutations affect oncogenes, tumor suppressor genes, or DNA repair genes.

2.2 Dose-Response Relationship

Radiation dose is quantified in sieverts (Sv), accounting for absorbed energy and radiation type. The Linear No-Threshold (LNT) model postulates a linear increase in cancer risk with dose, with no safe threshold:

$$Risk = \alpha \times Dose$$

Where $\alpha$ represents excess relative risk per unit dose. Data from Hiroshima/Nagasaki indicate:

• Leukemia: α ≈ 0.05–0.1 per Sv
• Solid cancers: α ≈ 0.04 per Sv

Age at exposure, dose rate, and radionuclide type significantly modify risk. For example, children exposed to Iodine-131 (Chernobyl) experienced dramatically higher thyroid cancer incidence.

2.3 Biological Modifiers

Factors affecting cancer risk include:

• Age: Younger individuals accumulate higher lifetime risk
• Sex: Differences in susceptibility exist; e.g., breast tissue radiation increases female risk
• Dose rate: Protracted low-dose exposures allow DNA repair, reducing per-unit dose risk
• Radionuclide type: Alpha emitters (like uranium isotopes) are highly damaging when internalized

---

3. Hiroshima and Nagasaki Atomic Bombings

3.1 Historical Context

• Dates: Hiroshima (August 6, 1945), Nagasaki (August 9, 1945)
• Detonation energy: ~15–21 kilotons TNT equivalent
• Immediate radiation: ~4–6 Gy near ground zero

Exposure included a high-intensity pulse of gamma and neutron radiation, followed by environmental fallout.

3.2 Life Span Study (LSS)

The Life Span Study cohort by RERF followed over 120,000 survivors, both exposed and unexposed. Key outcomes:

• Leukemia: Sharp increase within 2–5 years post-exposure
• Solid cancers: Linear increase with dose, persisting decades
• Excess relative risk: Dose-dependent, with α ≈ 0.05–0.2 per Sv

Quantitative modeling allows projection of excess lifetime cancer incidence:

• ~1% increase per 100 mSv for leukemia
• ~0.5% per 100 mSv for solid cancers

Annotated Reference:
RERF. (2012). Life Span Study of Atomic Bomb Survivors. Radiation Research, 177(3), 229–247.
Summary: Detailed cohort analysis confirms dose-dependent increase in leukemia and solid cancers; provides critical parameters for quantitative modeling.

---

4. Chernobyl Nuclear Disaster

4.1 Incident Overview

• Date: April 26, 1986
• Reactor explosion released ~5 exabecquerels of radioactivity, including I-131, Cs-137, Sr-90
• Exposure: Mixed, chronic (external and internal via ingestion/inhalation)

4.2 Health Outcomes

• Thyroid cancer: Dramatic rise in children, linked to I-131 exposure

• Leukemia: Observed in cleanup workers (liquidators) but statistically less clear
• Other solid tumors: Some elevation in long-term studies

Average thyroid doses ranged 0–50 Gy for children in contaminated zones.

Annotated Reference:
Cardis, E., et al. (2005). Estimates of Cancer Risks from the Chernobyl Accident. Radiation Research, 163(3), 247–259.
Summary: Dose-response modeling establishes strong correlation between I-131 exposure and thyroid cancer in children; supports extrapolation to low-dose risk assessment.

---

5. Depleted Uranium in Modern Conflicts

5.1 Properties and Uses

• DU: By-product of uranium enrichment, low U-235
• Utilized in munitions for armor-piercing capabilities
• Emits alpha radiation; highly toxic chemically

5.2 Health Evidence

• Animal studies: Internalized DU causes DNA damage and nephrotoxicity
• Epidemiology: Gulf War veterans and Iraq civilian populations show suggestive, but inconsistent genotoxic effects
• Risk modeling: Chronic low-dose DU exposure → theoretical lifetime cancer risk 0.01–0.05 per Sv

Annotated Reference:
UNSCEAR. (2000). Sources and Effects of Ionizing Radiation, Annex D. United Nations.
Summary: Reviews DU exposure studies and theoretical cancer risks; emphasizes uncertainties in population-level effects.

---

6. Quantitative Risk Modeling

6.1 Methodology

Using the LNT model and historical data:

• Acute high-dose exposure: Hiroshima/Nagasaki, 4–6 Gy → 0.2–0.5 excess lifetime cancer deaths per Sv
• Chronic low-dose exposure: DU inhalation, 0.1–0.5 Sv → 0.01–0.05 excess cancer deaths per Sv

6.2 Comparative Table

Scenario	Dose (Sv)	Excess Lifetime Cancer Risk	Notes
Hiroshima/Nagasaki	4–6	0.2–0.5	Acute, high-dose
Chernobyl (thyroid)	0–50	0.1–0.3	Internal I-131, chronic
DU battlefield exposure	0.1–0.5	0.01–0.05	Chronic, low-dose

6.3 Modern Scenario: Iran Conflict

• DU use or enrichment facility damage could expose workers to 1–5 Sv (localized)
• General population exposure would be much lower (<0.1 Sv)
• Risk modeling suggests measurable but small population-level cancer increase, mitigated by evacuation, shielding, and monitoring

---

7. Discussion

7.1 Key Insights

• Historical events provide robust dose-response data for acute exposures
• Chronic, low-dose exposures remain challenging to quantify; models provide theoretical estimates
• Depleted uranium exposure presents both radiological and chemical risk

7.2 Limitations

• Low-dose epidemiology is affected by confounding, migration, and mixed exposures
• Risk models (e.g., LNT) have uncertainty, especially for <100 mSv
• Data gaps exist for modern conflict scenarios due to lack of large, monitored cohorts

7.3 Policy Implications

• Transparent monitoring of radiation and health outcomes is essential
• International guidelines (IAEA, WHO, UNSCEAR) inform protective measures
• Mitigation strategies: shielding, evacuation, decontamination, public education

---

8. Conclusion

Ionizing radiation is a verified carcinogen with dose-dependent effects. Hiroshima, Nagasaki, and Chernobyl provide quantitative evidence for modeling risk. Modern conflict scenarios, such as potential DU exposure or nuclear facility damage, are theoretically hazardous but pose much lower risk than historical high-dose events. Ongoing monitoring, protective strategies, and public awareness are crucial for minimizing radiation-related health impacts.

---

Annotated References

1. RERF. (2012). Life Span Study of Atomic Bomb Survivors. Radiation Research, 177(3), 229–247.
   Comprehensive cohort study of 120,000 survivors; establishes dose-dependent risk for leukemia and solid cancers.
2. Cardis, E., et al. (2005). Estimates of Cancer Risks from the Chernobyl Accident. Radiation Research, 163(3), 247–259.
   Dose-response modeling confirms high thyroid cancer risk in children exposed to I-131.
3. UNSCEAR. (2000). Sources and Effects of Ionizing Radiation, Annex D. United Nations.
   Reviews depleted uranium exposure studies; highlights uncertainty in low-dose risk.
4. IAEA. (2006). Chernobyl’s Legacy: Health, Environmental and Socio-Economic Impacts.
   Official health outcomes report for affected populations and cleanup workers.
5. BEIR VII Committee. (2006). Health Risks from Exposure to Low Levels of Ionizing Radiation. National Academies Press.
   Comprehensive low-dose radiation risk assessment, provides LNT model parameters.
6. Shields, P., et al. (2010). Depleted Uranium Toxicology: Implications for Military Exposures. Toxicology, 278(2), 82–93.
   Reviews biological effects of DU, genotoxicity, and epidemiological evidence in veterans.
7. Little, M.P., et al. (2012). A Review of Dose-Response Models for Radiation-Induced Cancer. International Journal of Radiation Biology, 88(10), 743–759.
   Comparison of LNT, threshold, and hormesis models for radiation exposure.
8. WHO. (2006). Ionizing Radiation, Health Effects, and Protective Measures.
   Guidelines for public health response to radiation exposure.
9. UNSCEAR. (2016). Effects of Ionizing Radiation: 2016 Report to the General Assembly.
   Updates on long-term cancer incidence in exposed populations.
10. Darby, S.C., et al. (2005). Risk of Cancer from Low-Level Radiation Exposure. The Lancet, 365(9477), 1461–1467.
    Meta-analysis of low-dose exposures and excess relative risk estimates.

Article By: Brian Opiyo 

 

7 Hygiene Mistakes Almost Everyone Makes Daily (And What to Do Instead)

Introduction 

In a world where cleanliness is often equated with health, many people assume that the more they clean their bodies, the better. However, modern medical research shows that some common hygiene habits may actually do more harm than good.

From overwashing to using the wrong products, these everyday mistakes can disrupt your body’s natural balance, weaken your skin barrier, and even increase the risk of infections.

This article explores seven common hygiene mistakes, backed by science, and provides practical, doctor-approved alternatives to help you maintain optimal health.

Understanding Your Body’s Natural Balance

The human body is not meant to be sterile. Your skin and intimate areas host a complex ecosystem of beneficial microorganisms known as the microbiome. These bacteria play a crucial role in protecting against harmful pathogens, maintaining pH balance, and supporting overall health.

For example, healthy vaginal flora is dominated by Lactobacillus species, which help maintain an acidic environment (pH 3.5–4.5)[1]. Disrupting this balance can lead to infections such as bacterial vaginosis and yeast infections.

Similarly, your skin has a slightly acidic pH that acts as a natural defense barrier. When this balance is disturbed, irritation and inflammation can occur.

Understanding this concept is key: good hygiene is about balance, not excessive cleaning.

1. Overwashing Your Body

Many people believe that showering multiple times a day is beneficial, especially in hot climates or after sweating. However, excessive washing can strip your skin of its natural oils and protective bacteria[6].

Frequent use of soap—especially harsh soaps—can damage the skin barrier, leading to dryness, irritation, and increased sensitivity. Over time, this may make your skin more vulnerable to infections and environmental damage.

What to do instead:
Limit showers to once per day unless necessary. Use lukewarm water rather than hot water, and focus cleansing on areas prone to sweat, such as the underarms, feet, and groin.

2. Using Harsh or Scented Soaps

Scented soaps and body washes may smell pleasant, but they often contain chemicals that can irritate the skin and disrupt its natural pH[6].

Most traditional soaps are alkaline, while the skin’s natural pH is slightly acidic. This mismatch can weaken the skin’s protective barrier, leading to dryness, itching, and inflammation. Fragrances and artificial additives can also trigger allergic reactions in sensitive individuals.

What to do instead:
Choose mild, fragrance-free, and pH-balanced cleansers. These products clean without stripping away essential oils or disrupting your skin’s natural balance.

3. Washing Inside the Vagina (Douching)

One of the most widespread hygiene myths is that the vagina needs internal cleaning. In reality, the vagina is self-cleaning and does not require douching or internal washing[1][2][7].

Douching can disrupt the natural bacterial balance, eliminating beneficial bacteria and allowing harmful organisms to thrive. This can increase the risk of infections such as bacterial vaginosis, yeast infections, and pelvic inflammatory disease.

What to do instead:
Clean only the external genital area (the vulva) using water or a mild cleanser. Avoid inserting any products inside the vagina unless prescribed by a healthcare professional.

4. Overcleaning Intimate Areas

Even without douching, washing the intimate area too frequently can cause problems. Many people wash multiple times a day to prevent odor, but this can actually make things worse[8].

Excessive cleaning can dry out sensitive tissues, disrupt natural flora, and increase the risk of irritation and infection.

What to do instead:
Wash the intimate area once daily under normal conditions. During menstruation or after heavy sweating, washing twice daily may be appropriate—but avoid overdoing it.

5. Wearing Tight, Non-Breathable Underwear

Clothing choices play a significant role in hygiene. Tight-fitting or synthetic underwear can trap heat and moisture, creating an environment where bacteria and yeast can thrive[8].

This is particularly important for intimate health, as warm and moist conditions can increase the likelihood of infections and irritation.

What to do instead:
Opt for loose-fitting, breathable underwear made from natural fabrics like cotton. Change underwear daily, and avoid staying in sweaty clothes for extended periods.

6. Using Feminine Hygiene Products Unnecessarily

The market for feminine hygiene products has grown significantly, offering everything from scented sprays to wipes and washes. While these products are heavily marketed, many are unnecessary and can even be harmful[8].

They often contain fragrances, preservatives, and other chemicals that disrupt the natural microbiome and pH balance. This can lead to irritation, allergic reactions, and increased infection risk.

What to do instead:
Keep your routine simple. In most cases, water and a gentle cleanser are sufficient. Avoid using products with strong fragrances or unnecessary additives.

7. Not Drying Properly After Washing

After washing, many people overlook the importance of thoroughly drying their bodies. Moisture left on the skin—especially in folds or intimate areas—can create an ideal environment for fungal and bacterial growth[6][8].

This can lead to issues such as skin irritation, unpleasant odors, and infections.

What to do instead:
After bathing, gently pat your skin dry with a clean towel. Pay special attention to areas like the groin, underarms, and between skin folds. Avoid aggressive rubbing, as this can irritate the skin.

The Science Behind Healthy Hygiene

The key takeaway is that hygiene is not about eliminating all bacteria—it is about maintaining a healthy balance. Your body relies on beneficial microorganisms to protect against harmful ones. Disrupting this balance through excessive cleaning or harsh products can weaken your natural defenses.

Maintaining proper hygiene involves:

• Supporting your body’s natural pH
• Preserving beneficial bacteria
• Avoiding unnecessary chemical exposure

When these factors are in balance, your body is better equipped to protect itself.

A Simple, Healthy Hygiene Routine

To maintain good hygiene without harming your body, follow these basic guidelines:

• Shower once daily using lukewarm water
• Use mild, fragrance-free cleansers
• Avoid douching and internal cleansing
• Wear breathable, clean clothing
• Dry your body thoroughly after washing
• Keep your routine simple and consistent

When to Seek Medical Advice

While many hygiene-related issues can be resolved by adjusting your routine, some symptoms may require medical attention. Consult a healthcare professional if you experience:

• Persistent itching or irritation
• Unusual or strong odors
• Abnormal discharge
• Pain or discomfort

These symptoms may indicate an underlying condition that requires proper diagnosis and treatment.

Final Thoughts

Hygiene is essential for good health—but more is not always better. Many common habits, often believed to be beneficial, can disrupt your body’s natural balance and lead to long-term issues.

The goal of hygiene should not be to sterilize your body, but to support its natural protective systems. By avoiding these common mistakes and adopting a balanced approach, you can maintain healthier skin, better intimate health, and overall well-being.

Quick Summary

Avoid these common hygiene mistakes:

1. Overwashing your body
2. Using harsh or scented soaps
3. Douching
4. Overcleaning intimate areas
5. Wearing tight, non-breathable underwear
6. Using unnecessary hygiene products
7. Not drying properly

---

References

1. American College of Obstetricians and Gynecologists (ACOG) – Vaginal Health & Hygiene Guidelines: https://www.acog.org/womens-health/faqs/vaginitis
2. CDC – Bacterial Vaginosis (BV): https://www.cdc.gov/std/bv/stdfact-bacterial-vaginosis.htm
3. World Health Organization – Personal Hygiene & Health: https://www.who.int
4. Cleveland Clinic – Vaginal Care & Hygiene Advice: https://my.clevelandclinic.org
5. Mayo Clinic – Personal Hygiene & Skin Care: https://www.mayoclinic.org
6. NHS – Keeping Your Vagina Clean and Healthy: https://www.nhs.uk
7. International Journal of Women's Health – Impact of Feminine Hygiene Products on Vaginal Health: https://www.ijwh.org

By Brian Opiyo

Cancer Stem Cells & Tumor Recurrence: Why a Small Subset of Cells Drives Relapse

 

Introduction:

Despite advances in chemotherapy, radiation, and targeted therapies, many cancers return months or years after successful treatment. This recurrence is one of oncology’s greatest challenges. Emerging research reveals that the root cause often lies within a small population of resilient cells known as cancer stem cells (CSCs)—a subpopulation that can self-renew, differentiate, and survive hostile conditions that kill most tumor cells [1].

CSCs are thought to be the “master builders” of tumors, capable of regenerating the entire cancer mass even after 99% of it is destroyed. Understanding their biology has become essential to developing therapies that prevent relapse and achieve lasting remission.

1. What Are Cancer Stem Cells?

Cancer stem cells are a distinct subset within tumors that exhibit properties similar to normal stem cells, including:

• Self-renewal: the ability to replicate indefinitely

• Differentiation: the capacity to produce various cancer cell types

• Therapy resistance: survival under radiation or chemotherapy stress

These cells were first identified in leukemia in 1997 by Bonnet and Dick [2] and later in solid tumors such as breast, brain, prostate, and colon cancers. They represent less than 5% of total tumor cells but possess immense regenerative potential.

2. The Physiological Roots of Cancer Stem Cells

CSCs often originate from normal stem or progenitor cells that undergo genetic and epigenetic reprogramming, gaining malignant traits while retaining stemness features [3]. Key signaling pathways that maintain this self-renewal capacity include:

• Wnt/β-catenin pathway: promotes stemness and proliferation

• Notch signaling: maintains undifferentiated cell populations

• Hedgehog pathway: crucial for embryonic development and tumor initiation

Disruption in these pathways enables CSCs to continuously seed new tumor growth.

3. The Tumor Microenvironment — A Safe Haven for CSCs

The tumor microenvironment (TME) provides CSCs with a protective niche rich in cytokines, hypoxic zones, and extracellular matrix (ECM) signals that promote survival [4].

Within this environment:

• Hypoxia stabilizes hypoxia-inducible factors (HIFs) that promote stem cell markers such as CD133 and ALDH1 [5].

• Cancer-associated fibroblasts (CAFs) secrete growth factors like TGF-β, enhancing CSC renewal.

• Immune evasion mechanisms—such as PD-L1 expression—shield CSCs from T-cell attacks.

This interplay allows CSCs to stay dormant or slowly proliferate, evading chemotherapy and later reactivating to cause relapse.

4. Why Standard Therapies Often Fail

Most cancer treatments target rapidly dividing cells. CSCs, however, can enter a quiescent (sleep-like) state, becoming metabolically inactive and resistant to conventional drugs [6].

They also express high levels of ATP-binding cassette (ABC) transporters, such as ABCG2, which pump out toxic substances—including chemotherapy agents [7]. Additionally, CSCs exhibit robust DNA repair mechanisms and anti-apoptotic signaling, allowing them to survive radiation and reinitiate tumor growth once therapy stops.

This biological resilience explains why tumors may shrink temporarily after treatment but eventually return more aggressively.

5. Biomarkers and Detection of Cancer Stem Cells

Identifying CSCs involves specific surface markers that vary by tumor type:

• CD44+, CD24−/low → Breast and prostate cancer

• CD133+ → Brain and colon cancer

• ALDH1+ → Ovarian and pancreatic cancer [8]

These markers aid in isolating CSCs for diagnostic purposes and designing targeted therapies aimed directly at eradicating them.

6. Therapeutic Strategies Targeting CSCs

a. Targeting Signaling Pathways

Drugs that inhibit CSC-maintaining pathways (e.g., Wnt, Hedgehog, and Notch inhibitors) are in advanced clinical trials. For instance, Vismodegib, a Hedgehog pathway inhibitor, has shown efficacy in basal cell carcinoma [9].

b. Epigenetic Therapy

Epigenetic modulators such as histone deacetylase (HDAC) inhibitors and DNA methyltransferase inhibitors can reverse the stem-like state, sensitizing CSCs to chemotherapy [10].

c. Immunotherapy

Emerging approaches use CSC-targeted vaccines and CAR-T cells engineered to recognize CSC antigens like CD133, enhancing immune clearance [11].

d. Metabolic Reprogramming

CSCs exhibit altered metabolism—favoring glycolysis and oxidative phosphorylation flexibility. Targeting metabolic enzymes such as ALDH or IDH1 may disrupt their survival advantage [12].

7. The Future: Combining CSC Therapy with Precision Medicine

The integration of genomic, transcriptomic, and metabolomic data now enables personalized strategies to identify CSC vulnerabilities. Researchers envision combination therapies that target CSCs alongside the tumor bulk, drastically reducing relapse rates [13].

Artificial intelligence and machine learning are also being used to predict which patients have CSC-driven tumors, enabling early intervention [14].

---

Conclusion

Cancer stem cells represent the heart of tumor recurrence. Their remarkable ability to self-renew, resist therapy, and adapt underlies the challenge of long-term cancer control.
To truly cure cancer, medicine must not only kill the tumor—but also eliminate its roots.

Future oncology must focus on therapies that disrupt CSC niches, reprogram their metabolism, and activate the immune system against them. By targeting these master cells, we can turn remission into permanent recovery.

---

References

1. Clarke, M. F., et al. (2023). Cancer stem cells: Perspectives on current status and future directions. Nature Reviews Cancer, 23(2), 87–105.

2. Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3(7), 730–737.

3. Li, X., et al. (2024). Epigenetic reprogramming and stemness in cancer development. Cell Reports, 46(3), 101–118.

4. Batlle, E., & Clevers, H. (2023). Cancer stem cells revisited: The cell of origin, niche, and therapeutic targeting. Science, 379(6638), 159–170.

5. Semenza, G. L. (2024). Hypoxia-inducible factors in cancer physiology. Annual Review of Physiology, 86, 211–234.

6. Patel, M., et al. (2024). Quiescence and therapy resistance in cancer stem cells. Trends in Cancer, 10(1), 33–45.

7. Dean, M., Fojo, T., & Bates, S. (2023). Tumour stem cells and drug resistance. Nature Reviews Cancer, 23(4), 289–302.

8. Liu, J., et al. (2023). Cancer stem cell markers and their clinical relevance. Frontiers in Oncology, 13(5), 998–1012.

9. Tang, D., et al. (2024). Clinical progress of Hedgehog pathway inhibitors in oncology. Cancer Treatment Reviews, 124, 102495.

10. Gupta, P., et al. (2024). Epigenetic modulation of cancer stem cells: Therapeutic implications. Nature Medicine, 30(3), 480–492.

11. Wang, L., et al. (2025). CAR-T cell therapy targeting cancer stem cell antigens. Nature Biotechnology, 43(2), 221–238.

12. Chen, X., et al. (2025). Metabolic plasticity in cancer stem cells: Emerging therapeutic targets. Cell Metabolism, 37(1), 45–62.

13. Qiu, R., et al. (2024). Integrating multi-omic profiles for cancer stem cell-targeted therapy. Nature Communications, 15(1), 5563.

14. Kumar, S., & Yang, Z. (2025). AI-driven precision oncology for CSC identification and targeting. Frontiers in Cancer Research, 18(2), 114–132.

Article By:

Brian Opiyo